Results for levonorgestrela translation from Slovenian to English

vpliv na peroralne kontraceptive (0,03 mg etinilestradiola in 0,15 mg levonorgestrela)
effect on oral contraceptive (0.03 mg ethinylestradiol and 0.15 mg levonorgestrel)

zdravilo fycompa lahko povzroči manjšo učinkovitost nekaterih hormonskih kontraceptivov, npr. levonorgestrela.
fycompa may make certain hormonal contraceptives such as levonorgestrel less effective.

pri sočasnem jemanju 5 mg linagliptina se farmakokinetika levonorgestrela ali etinilestradiola v stanju dinamičnega ravnovesja ni spremenila.
co-administration with 5 mg linagliptin did not alter the steady-state pharmacokinetics of levonorgestrel or ethinylestradiol.

med sočasno uporabo levonorgestrela in etinilestradiola s ticagrelorjem ni pričakovati klinično pomembnega vpliva na učinkovitost peroralnih kontraceptivov.
no clinically relevant effect on oral contraceptive efficacy is expected when levonorgestrel and ethinyl estradiol are co-administered with ticagrelor.

med sočasno uporabo levonorgestrela in etinilestradiola z zdravilom possia ni pričakovati klinično pomembnega vpliva na učinkovitost peroralnih kontraceptivov.
no clinically relevant effect on oral contraceptive efficacy is expected when levonorgestrel and ethinyl estradiol are co-administered with possia.

peroralni kontraceptivi: pri sočasnem dajanju 5 mg linagliptina se farmakokinetika levonorgestrela ali etinilestradiola v dinamičnem ravnovesju ni spremenila.
oral contraceptives: co-administration with 5 mg linagliptin did not alter the steady-state pharmacokinetics of levonorgestrel or ethinylestradiol.

sočasna uporaba peroralnih kontraceptivov (30 g etinilestradiola in 150 g levonorgestrela) ni vplivala na peroralno farmakokinetiko sildenafila.
co-administration of oral contraceptives (ethinyloestradiol 30 g and levonorgestrel 150 g) did not affect the oral pharmacokinetics of sildenafil.

peroralni sildenafil nima klinično pomembnega vpliva na koncentracijo peroralnih kontraceptivov (30 g etinilestradiola in 150 g levonorgestrela) v plazmi.
oral sildenafil had no clinically significant impact on the plasma levels of oral contraceptives (ethinyloestradiol 30 g and levonorgestrel 150 g).

sočasna uporaba zdravila possia ter levonorgestrela in etinilestradiola je povečala izpostavljenost etinilestradiolu za približno 20 %, farmakokinetike levonorgestrela pa ni spremenila.
co-administration of possia and levonorgestrel and ethinyl estradiol increased ethinyl estradiol exposure approximately 20% but did not alter the pharmacokinetics of levonorgestrel.

sočasna uporaba fingolimoda in peroralnih kontracepcijskih sredstev (etinilestradiola in levonorgestrela) ni povzročila nobene spremembe glede izpostavljenosti peroralnim kontracepcijskim sredstvom.
co-administration of fingolimod with oral contraceptives (ethinylestradiol and levonorgestrel) did not elicit any change in oral contraceptive exposure.

vpliv zmernega povečanja očistka levonorgestrela in sprememb fsh in lh v serumu na ovulacijsko aktivnost jajčnikov ni znan (glejte poglavje 4. 4).
the impact of the modest increase in levonorgestrel clearance, and the changes in serum fsh and lh, on ovarian ovulatory activity is unknown (see section 4.4).

ni še znano, kakšno je tveganje za vte pri chc, ki vsebujejo nomegestrolacetat v kombinaciji z estradiolom, v primerjavi s tveganjem pri chc, ki vsebujejo majhen odmerek levonorgestrela.
it is not yet known how the risk of vte with chcs that contain nomegestrol acetate in combination with estradiol compares with the risk with low dose levonorgestrel-containing chcs.

dajanje kombiniranega peroralnega kontraceptiva (30 μg etinilestradiola in 150 μg levonorgestrela) eno uro pred dajanjem eksenatida v obliki s takojšnim sproščanjem ni spremenilo auc, cmax ali cmin etinilestradiola ali levonorgestrela.
administration of a combination oral contraceptive (30 mcg ethinyl estradiol plus 150 mcg levonorgestrel) one hour before immediate-release exenatide did not alter the auc, cmax or cmin of either ethinyl estradiol or levonorgestrel.

maravirok ni klinično pomembno vplival na farmakokinetiko midazolama, peroralnih kontraceptivov etinilestradiola in levonorgestrela, ali na razmerje med 6β-hidroksikortizolom in kortizolom v urinu, kar kaže na odsotnost zaviranja ali indukcije cyp3a4 in vivo.
maraviroc had no clinically relevant effect on the pharmacokinetics of midazolam, the oral contraceptives ethinylestradiol and levonorgestrel, or urinary 6β-hydroxycortisol/cortisol ratio, suggesting no inhibition or induction of cyp3a4 in vivo.

levetiracetam v odmerku 1000 mg na dan ni vplival na farmakokinetiko peroralnih kontraceptivov (etinilestradiola in levonorgestrela); endokrini parametri (luteinizirajoči hormon in progesteron) se niso spremenili.
levetiracetam 1,000 mg daily did not influence the pharmacokinetics of oral contraceptives (ethinyl- estradiol and levonorgestrel); endocrine parameters (luteinizing hormone and progesterone) were not modified.

dajanje kombinacije peroralnega kontraceptiva (30 μg etinilestradiola in 150 μg levonorgestrela) eno uro pred dajanjem eksenatida v obliki s takojšnjim sproščanjem (10 μg dvakrat na dan) ni spremenilo auc, cmax ali cmin etinilestradiola ali levonorgestrela.
administration of a combination oral contraceptive (30 mcg ethinyl estradiol plus 150 mcg levonorgestrel) one hour before immediate-release exenatide (10 mcg bid) did not alter the auc, cmax or cmin of either ethinyl estradiol or levonorgestrel.